GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » RPG Life Sciences Ltd (NSE:RPGLIFE) » Definitions » EV-to-EBIT

RPG Life Sciences (NSE:RPGLIFE) EV-to-EBIT : 14.91 (As of Jun. 01, 2025)


View and export this data going back to 2008. Start your Free Trial

What is RPG Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RPG Life Sciences's Enterprise Value is ₹34,816 Mil. RPG Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹2,335 Mil. Therefore, RPG Life Sciences's EV-to-EBIT for today is 14.91.

The historical rank and industry rank for RPG Life Sciences's EV-to-EBIT or its related term are showing as below:

NSE:RPGLIFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.24   Med: 19.99   Max: 88.89
Current: 14.91

During the past 13 years, the highest EV-to-EBIT of RPG Life Sciences was 88.89. The lowest was 7.24. And the median was 19.99.

NSE:RPGLIFE's EV-to-EBIT is ranked better than
57.41% of 688 companies
in the Drug Manufacturers industry
Industry Median: 17.055 vs NSE:RPGLIFE: 14.91

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. RPG Life Sciences's Enterprise Value for the quarter that ended in Mar. 2025 was ₹35,022 Mil. RPG Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹2,335 Mil. RPG Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 6.67%.


RPG Life Sciences EV-to-EBIT Historical Data

The historical data trend for RPG Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RPG Life Sciences EV-to-EBIT Chart

RPG Life Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.08 11.64 11.35 20.31 15.00

RPG Life Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.31 21.80 35.88 31.07 15.00

Competitive Comparison of RPG Life Sciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RPG Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RPG Life Sciences's EV-to-EBIT falls into.


;
;

RPG Life Sciences EV-to-EBIT Calculation

RPG Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=34816.200/2335
=14.91

RPG Life Sciences's current Enterprise Value is ₹34,816 Mil.
RPG Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,335 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RPG Life Sciences  (NSE:RPGLIFE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

RPG Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=2335/35021.55545
=6.67 %

RPG Life Sciences's Enterprise Value for the quarter that ended in Mar. 2025 was ₹35,022 Mil.
RPG Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,335 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RPG Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of RPG Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


RPG Life Sciences Business Description

Traded in Other Exchanges
Address
463, Dr. Annie Besant Road, RPG House, Near Old Passport Office, Worli, Mumbai, MH, IND, 400030
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.

RPG Life Sciences Headlines

No Headlines